Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer
The aim of the study is to assess the value of carbonic anhydrase isozyme IX (CA IX) expression as a predictor of disease-free survival (DFS) and disease-specific survival (DSS) in rectal cancer treated by preoperative radio- or chemoradiotherapy or surgery only. Archival tumour samples from 166 pat...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2009-03, Vol.100 (6), p.874-880 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 880 |
|---|---|
| container_issue | 6 |
| container_start_page | 874 |
| container_title | British journal of cancer |
| container_volume | 100 |
| creator | Korkeila, E Talvinen, K Jaakkola, P M Minn, H Syrjänen, K Sundström, J Pyrhönen, S |
| description | The aim of the study is to assess the value of carbonic anhydrase isozyme IX (CA IX) expression as a predictor of disease-free survival (DFS) and disease-specific survival (DSS) in rectal cancer treated by preoperative radio- or chemoradiotherapy or surgery only. Archival tumour samples from 166 patients were analysed for CA IX expression by three different evaluations: positive/negative, proportion of positivity and staining intensity. The results of immunohistochemical analysis were confirmed by demonstrating CA IX protein in western blotting analysis. Forty-four percent of the operative samples were CA IX positive, of these 34% had weak and 66% moderate/strong staining intensity. In univariate survival analysis, intensity of CA IX expression was a predictor of DFS (
P
=0.003) and DSS (
P
=0.034), both being markedly longer in tumours with negative or weakly positive staining. In multivariate Cox model, number of metastatic lymph nodes and CA IX intensity were the only independent predictors of DFS. Carbonic anhydrase isozyme IX intensity was the only independent predictor of DSS, with HR=9.2 for dying of disease with moderate-intense CA IX expression as compared with CA IX-negative/weak cases. Negative/weak CA IX staining intensity is an independent predictor of longer DFS and DSS in rectal cancer. |
| doi_str_mv | 10.1038/sj.bjc.6604949 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2661792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67039318</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-663dd9a0501f9663141dbc3b479ece53ef113b9a81aef876240f5d8efff044283</originalsourceid><addsrcrecordid>eNp1kc9rFTEQx4Mo9rV69ShBsLd9zY_dZHMRpFStFLwoeAvZ7OR1l33JM7Mr9r835S2tCp7CMJ_5znfyJeQVZ1vOZHuB47Yb_VYpVpvaPCEb3khR8Vbop2TDGNMVM4KdkFPEsZSGtfo5OeFG1EwLtiGfr34dMiAOKdIUqHe5S3Hw1MXbuz47BHr9neKy2wHOSA8pZZqW2ac90CHSDH52U5mKHvIL8iy4CeHl-p6Rbx-uvl5-qm6-fLy-fH9T-abhc6WU7HvjWMN4MKXgNe87L7taG_DQSAicy864ljsIrVbFaWj6FkIIrK5FK8_Iu6PuYen20HuIc3aTPeRh7_KdTW6wf3ficGt36acVSnFtRBE4XwVy-rGUw-x-QA_T5CKkBa3STBrJ7ze9-Qcc05JjOc4KYUxbS64KtD1CPifEDOHBCWf2PiOLoy0Z2TWjMvD6T_-P-BpKAd6ugEPvppDL9w74wAluZKuELtzFkcPSijvIj_b-s_o3pESrPg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229984316</pqid></control><display><type>article</type><title>Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Korkeila, E ; Talvinen, K ; Jaakkola, P M ; Minn, H ; Syrjänen, K ; Sundström, J ; Pyrhönen, S</creator><creatorcontrib>Korkeila, E ; Talvinen, K ; Jaakkola, P M ; Minn, H ; Syrjänen, K ; Sundström, J ; Pyrhönen, S</creatorcontrib><description>The aim of the study is to assess the value of carbonic anhydrase isozyme IX (CA IX) expression as a predictor of disease-free survival (DFS) and disease-specific survival (DSS) in rectal cancer treated by preoperative radio- or chemoradiotherapy or surgery only. Archival tumour samples from 166 patients were analysed for CA IX expression by three different evaluations: positive/negative, proportion of positivity and staining intensity. The results of immunohistochemical analysis were confirmed by demonstrating CA IX protein in western blotting analysis. Forty-four percent of the operative samples were CA IX positive, of these 34% had weak and 66% moderate/strong staining intensity. In univariate survival analysis, intensity of CA IX expression was a predictor of DFS (
P
=0.003) and DSS (
P
=0.034), both being markedly longer in tumours with negative or weakly positive staining. In multivariate Cox model, number of metastatic lymph nodes and CA IX intensity were the only independent predictors of DFS. Carbonic anhydrase isozyme IX intensity was the only independent predictor of DSS, with HR=9.2 for dying of disease with moderate-intense CA IX expression as compared with CA IX-negative/weak cases. Negative/weak CA IX staining intensity is an independent predictor of longer DFS and DSS in rectal cancer.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6604949</identifier><identifier>PMID: 19240720</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Aged ; Angiogenesis ; Antigens, Neoplasm - analysis ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cancer Research ; Cancer therapies ; Carbonic Anhydrase IX ; Carbonic Anhydrases - analysis ; Chemotherapy ; Clinical Study ; Colorectal cancer ; Drug Resistance ; Epidemiology ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Hypoxia ; Immunohistochemistry ; Lymphatic system ; Male ; Medical prognosis ; Medical research ; Medical sciences ; Molecular Medicine ; Oncology ; Prognosis ; Proportional Hazards Models ; Radiation therapy ; Rectal Neoplasms - enzymology ; Rectal Neoplasms - mortality ; Rectal Neoplasms - therapy ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Surgery ; Survival analysis ; Tumors</subject><ispartof>British journal of cancer, 2009-03, Vol.100 (6), p.874-880</ispartof><rights>The Author(s) 2009</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Mar 24, 2009</rights><rights>Copyright © 2009 Cancer Research UK 2009 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-663dd9a0501f9663141dbc3b479ece53ef113b9a81aef876240f5d8efff044283</citedby><cites>FETCH-LOGICAL-c551t-663dd9a0501f9663141dbc3b479ece53ef113b9a81aef876240f5d8efff044283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661792/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661792/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21938627$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19240720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Korkeila, E</creatorcontrib><creatorcontrib>Talvinen, K</creatorcontrib><creatorcontrib>Jaakkola, P M</creatorcontrib><creatorcontrib>Minn, H</creatorcontrib><creatorcontrib>Syrjänen, K</creatorcontrib><creatorcontrib>Sundström, J</creatorcontrib><creatorcontrib>Pyrhönen, S</creatorcontrib><title>Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>The aim of the study is to assess the value of carbonic anhydrase isozyme IX (CA IX) expression as a predictor of disease-free survival (DFS) and disease-specific survival (DSS) in rectal cancer treated by preoperative radio- or chemoradiotherapy or surgery only. Archival tumour samples from 166 patients were analysed for CA IX expression by three different evaluations: positive/negative, proportion of positivity and staining intensity. The results of immunohistochemical analysis were confirmed by demonstrating CA IX protein in western blotting analysis. Forty-four percent of the operative samples were CA IX positive, of these 34% had weak and 66% moderate/strong staining intensity. In univariate survival analysis, intensity of CA IX expression was a predictor of DFS (
P
=0.003) and DSS (
P
=0.034), both being markedly longer in tumours with negative or weakly positive staining. In multivariate Cox model, number of metastatic lymph nodes and CA IX intensity were the only independent predictors of DFS. Carbonic anhydrase isozyme IX intensity was the only independent predictor of DSS, with HR=9.2 for dying of disease with moderate-intense CA IX expression as compared with CA IX-negative/weak cases. Negative/weak CA IX staining intensity is an independent predictor of longer DFS and DSS in rectal cancer.</description><subject>Aged</subject><subject>Angiogenesis</subject><subject>Antigens, Neoplasm - analysis</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Carbonic Anhydrase IX</subject><subject>Carbonic Anhydrases - analysis</subject><subject>Chemotherapy</subject><subject>Clinical Study</subject><subject>Colorectal cancer</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Immunohistochemistry</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Radiation therapy</subject><subject>Rectal Neoplasms - enzymology</subject><subject>Rectal Neoplasms - mortality</subject><subject>Rectal Neoplasms - therapy</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Surgery</subject><subject>Survival analysis</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc9rFTEQx4Mo9rV69ShBsLd9zY_dZHMRpFStFLwoeAvZ7OR1l33JM7Mr9r835S2tCp7CMJ_5znfyJeQVZ1vOZHuB47Yb_VYpVpvaPCEb3khR8Vbop2TDGNMVM4KdkFPEsZSGtfo5OeFG1EwLtiGfr34dMiAOKdIUqHe5S3Hw1MXbuz47BHr9neKy2wHOSA8pZZqW2ac90CHSDH52U5mKHvIL8iy4CeHl-p6Rbx-uvl5-qm6-fLy-fH9T-abhc6WU7HvjWMN4MKXgNe87L7taG_DQSAicy864ljsIrVbFaWj6FkIIrK5FK8_Iu6PuYen20HuIc3aTPeRh7_KdTW6wf3ficGt36acVSnFtRBE4XwVy-rGUw-x-QA_T5CKkBa3STBrJ7ze9-Qcc05JjOc4KYUxbS64KtD1CPifEDOHBCWf2PiOLoy0Z2TWjMvD6T_-P-BpKAd6ugEPvppDL9w74wAluZKuELtzFkcPSijvIj_b-s_o3pESrPg</recordid><startdate>20090324</startdate><enddate>20090324</enddate><creator>Korkeila, E</creator><creator>Talvinen, K</creator><creator>Jaakkola, P M</creator><creator>Minn, H</creator><creator>Syrjänen, K</creator><creator>Sundström, J</creator><creator>Pyrhönen, S</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090324</creationdate><title>Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer</title><author>Korkeila, E ; Talvinen, K ; Jaakkola, P M ; Minn, H ; Syrjänen, K ; Sundström, J ; Pyrhönen, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-663dd9a0501f9663141dbc3b479ece53ef113b9a81aef876240f5d8efff044283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Angiogenesis</topic><topic>Antigens, Neoplasm - analysis</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Carbonic Anhydrase IX</topic><topic>Carbonic Anhydrases - analysis</topic><topic>Chemotherapy</topic><topic>Clinical Study</topic><topic>Colorectal cancer</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Immunohistochemistry</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Radiation therapy</topic><topic>Rectal Neoplasms - enzymology</topic><topic>Rectal Neoplasms - mortality</topic><topic>Rectal Neoplasms - therapy</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Surgery</topic><topic>Survival analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Korkeila, E</creatorcontrib><creatorcontrib>Talvinen, K</creatorcontrib><creatorcontrib>Jaakkola, P M</creatorcontrib><creatorcontrib>Minn, H</creatorcontrib><creatorcontrib>Syrjänen, K</creatorcontrib><creatorcontrib>Sundström, J</creatorcontrib><creatorcontrib>Pyrhönen, S</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Korkeila, E</au><au>Talvinen, K</au><au>Jaakkola, P M</au><au>Minn, H</au><au>Syrjänen, K</au><au>Sundström, J</au><au>Pyrhönen, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2009-03-24</date><risdate>2009</risdate><volume>100</volume><issue>6</issue><spage>874</spage><epage>880</epage><pages>874-880</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>The aim of the study is to assess the value of carbonic anhydrase isozyme IX (CA IX) expression as a predictor of disease-free survival (DFS) and disease-specific survival (DSS) in rectal cancer treated by preoperative radio- or chemoradiotherapy or surgery only. Archival tumour samples from 166 patients were analysed for CA IX expression by three different evaluations: positive/negative, proportion of positivity and staining intensity. The results of immunohistochemical analysis were confirmed by demonstrating CA IX protein in western blotting analysis. Forty-four percent of the operative samples were CA IX positive, of these 34% had weak and 66% moderate/strong staining intensity. In univariate survival analysis, intensity of CA IX expression was a predictor of DFS (
P
=0.003) and DSS (
P
=0.034), both being markedly longer in tumours with negative or weakly positive staining. In multivariate Cox model, number of metastatic lymph nodes and CA IX intensity were the only independent predictors of DFS. Carbonic anhydrase isozyme IX intensity was the only independent predictor of DSS, with HR=9.2 for dying of disease with moderate-intense CA IX expression as compared with CA IX-negative/weak cases. Negative/weak CA IX staining intensity is an independent predictor of longer DFS and DSS in rectal cancer.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19240720</pmid><doi>10.1038/sj.bjc.6604949</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2009-03, Vol.100 (6), p.874-880 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2661792 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Aged Angiogenesis Antigens, Neoplasm - analysis Biological and medical sciences Biomedical and Life Sciences Biomedicine Biopsy Cancer Research Cancer therapies Carbonic Anhydrase IX Carbonic Anhydrases - analysis Chemotherapy Clinical Study Colorectal cancer Drug Resistance Epidemiology Female Gastroenterology. Liver. Pancreas. Abdomen Humans Hypoxia Immunohistochemistry Lymphatic system Male Medical prognosis Medical research Medical sciences Molecular Medicine Oncology Prognosis Proportional Hazards Models Radiation therapy Rectal Neoplasms - enzymology Rectal Neoplasms - mortality Rectal Neoplasms - therapy Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Surgery Survival analysis Tumors |
| title | Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A52%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20carbonic%20anhydrase%20IX%20suggests%20poor%20outcome%20in%20rectal%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Korkeila,%20E&rft.date=2009-03-24&rft.volume=100&rft.issue=6&rft.spage=874&rft.epage=880&rft.pages=874-880&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6604949&rft_dat=%3Cproquest_pubme%3E67039318%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229984316&rft_id=info:pmid/19240720&rfr_iscdi=true |